ArticleEuropean radiology2020
Time-to-enhancement at ultrafast breast DCE-MRI: potential imaging biomarker of tumour aggressiveness.
Article in European radiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.
- The diagnostic performance of ultrafast MRI to differentiate benign from malignant breast lesions: a systematic review and meta-analysis.European radiology · 2024Pooled it
- Population arterial input function measured from low dose breast ultrafast dynamic contrast enhanced MRI and fitted with a new mathematic model.Magnetic resonance imaging · 2026Article
- Diagnostic performance of kinetic parameters of ultrafast breast MRI and their associations with immunohistopathological findings of breast carcinoma.Scientific reports · 2026Article
- Optimizing Abbreviated Breast MRI for Surveillance in Women with Personal History of Breast Cancer.Diagnostics (Basel, Switzerland) · 2026Article
- Early-phase semi-quantitative analysis versus full time-course quantitative modeling of ultrafast dynamic contrast-enhanced MRI for breast cancer diagnosis, molecular subtyping, and treatment response prediction.Insights into imaging · 2025Article
- Role of Ultrafast Dynamic Contrast-Enhanced MRI in Breast Cancer Prognostication: Correlation Between Early Kinetic Parameters and Tumor Aggressiveness and Histopathologic Characteristics.Journal of the Korean Society of Radiology · 2025Article
- A simplified method for generating maximum slope maps in ultrafast dynamic contrast-enhanced breast magnetic resonance imaging.Radiological physics and technology · 2025Article
- Development of a prediction model for HER2 low breast cancer using quantitative intra- and peri-tumoral heterogeneity and MRI features on high-spatial resolution ultrafast DCE-MRI.Quantitative imaging in medicine and surgery · 2025Article
- Abbreviated and Ultrafast Dynamic Contrast-enhanced (DCE) MR Imaging.Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine · 2025Review
- Superior performance in classification of breast cancer molecular subtype and histological factors by radiomics based on ultrafast MRI over standard MRI: evidence from a prospective study.La Radiologia medica · 2025Observational
- Article
- Relationship between kinetic parameters of ultrafast dynamic contrast-enhanced (DCE) MRI and tumor-infiltrating lymphocytes (TILs) in breast cancer.Japanese journal of radiology · 2025Article
- Ultrafast sequence-based prediction model and nomogram to differentiate additional suspicious lesions on preoperative breast MRI.European radiology · 2025Article
- Signal enhancement ratio of multi-phase contrast-enhanced MRI: an imaging biomarker for survival in pancreatic adenocarcinoma.European radiology · 2024Article
- Ultrafast MR imaging findings of 2 different subtypes in a male patient with bilateral breast cancer.Radiology case reports · 2024Article
- Ultrafast dynamic contrast-enhanced breast MRI with quantitative perfusion parameters in differentiating breast cancer: a study focusing on triple-negative and HER2 positive breast cancer.Frontiers in oncology · 2024Article
- Ultrafast MRI and T1 and T2 Radiomics for Predicting Invasive Components in Ductal Carcinoma in Situ Diagnosed With Percutaneous Needle Biopsy.Korean journal of radiology · 2023Article
- A multiparametric approach to predict triple-negative breast cancer including parameters derived from ultrafast dynamic contrast-enhanced MRI.European radiology · 2023Article
- Value for combination of TZhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2023Article
- Multiparametric MRI model with synthetic MRI, DWI multi-quantitative parameters, and differential sub-sampling with cartesian ordering enables BI-RADS 4 lesions diagnosis with high accuracy.Frontiers in oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 3 countries.
Funding
Abstract
objectivesThis study was conducted in order to investigate whether there is a correlation between the time-to-enhancement (TTE) in ultrafast MRI and histopathological characteristics of breast cancers.
methodsBetween January and August 2017, 274 consecutive breast cancer patients (mean age, 53.5 years; range, 25-80 years) who underwent ultrafast MRI and subsequent surgery were included for analysis. Ultrafast MRI scans were acquired using TWIST-VIBE or 4D TRAK-3D TFE sequences. TTE and maximum slope (MS) were derived from the ultrafast MRI. The repeated measures ANOVA, Mann-Whitney U test and Kruskal-Wallis H test were performed to compare the median TTE, MS and SER according to histologic type, histologic grade, ER/PR/HER2 positivity, level of Ki-67 and tumour subtype. For TTE calculation, intraclass correlation coefficient (ICC) was used to evaluate interobserver variability.
resultsThe median TTE of invasive cancers was shorter than that of in situ cancers (p < 0.001). In invasive cancers, large tumours showed shorter TTE than small tumours (p = 0.001). High histologic/nuclear grade cancers had shorter TTE than low to intermediate grade cancers (p < 0.001 and p < 0.001). HER2-positive cancers showed shorter TTE than HER2-negative cancers (p = 0.001). The median TTE of cancers with high Ki-67 was shorter than that of cancers with low Ki-67 (p < 0.001). ICC between two readers showed moderate agreement (0.516). No difference was found in the median MS or SER values according to the clinicopathologic features.
conclusionsThe median TTE of breast cancer in ultrafast MRI was shorter in invasive or aggressive tumours than in in situ cancer or less aggressive tumours, respectively. KEY POINTS: • Invasive breast tumours show a shorter TTE in ultrafast DCE-MRI than in situ cancers. • A shorter TTE in ultrafast DCE-MRI is associated with breast tumours of a large size, high histologic or nuclear grade, PR negativity, HER2 positivity and high Ki-67 level.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.